Pharmaust Share Price and Company Fundamentals



Price
$0.112
Change
0.002 (1.818%)
52 week
0.081 - 0.12

Last traded: Today at 3:55 AM

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer. PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumors, as well as initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Key Metrics

PE ratio

-

PB ratio

3.46

Dividend yield

Beta

0.65

Market cap

-

Enterprise value

-

Company profile

Primary activitiesTo develop its own drug discovery intellectual property as well as providing highly specialised medicinal and synthetic chemistry services on a contract basis to clients.
Industry / SectorBiotechnology / Healthcare
Websitehttps://www.pharmaust.com
Mailing address5/3 Brodie Hall Drive Bentley WA 6102 Australia
Phone / Fax61 8 9202 6814 / 61 8 9467 6111
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Pharmaust does not pay dividends.

Company Executives

As of Jan 2022, following are the company executives and directors listed on Pharmaust.

NameTitleAgeTotal Pay
Dr. Roger Aston B.Sc., BSc (Hons), Ph.D.Exec. Chairman & Acting CEO65284.7k
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICDFin. Director, Company Sec. & Non-Exec. Director43138k
Dr. Richard MollardChief Scientific Officer262.8k
Mr. Robert Charles BishopExec. Director140.16k
Dr. Martine KeenanChief Scientific Officer & Exec. Director of Epichem Pty Ltd158.23k
Mr. Colin La GaliaChief Exec. Officer of Epichem Pty Ltd280.62k

Profitability and management effectiveness

Profit margin

-36.57%

Operating margin

-34.81%

Return on assets

-7.33%

Return on equity

-15.37%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Pharmaust is and its enterprise value is .

The PAA's stocks Beta value is 0.65 making it 35% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Pharmaust (PAA)

Pharmaust (ASX:PAA) Frequently Asked Questions

1. What is Pharmaust's Stock Symbol?

Pharmaust trades on ASX under the ticker symbol "PAA".

2. What is Pharmaust's stock price today?

One share of PAA stock can currently be purchased for approximately $0.112.

3. How can I contact Pharmaust?

Pharmaust's mailing address is 5/3 Brodie Hall Drive Bentley WA 6102 Australia. The company can be reached via phone at 61 8 9202 6814.

4. What is Pharmaust's official website?

The official website of Pharmaust is https://www.pharmaust.com.

5. Which share registry manages Pharmaust's stock?

Pharmaust's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.